The complicated skin and skin structure infections drugs market size is expected to see strong growth in the next few years. It will grow to $13.78 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing healthcare expenditure, increasing investment in r&d activities, rising demand for novel antibiotics, increasing incidence of antibiotic-resistant infections, growing demand for personalized medicine. Major trends in the forecast period include advancements in wound care products, targeted antibiotics, digital health monitoring, natural and alternative remedies, global collaborations.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report
Segmentation & Regional Insights
The complicated skin and skin structure infections drugs market covered in this report is segmented –
1) By Active Ingredients: Delafloxacin; Vancomycin; Ceftaroline Fosamil; Linezolid; Other Active Ingredients
2) By Route of Administration: Oral; Topical; Parenteral
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 2023. The regions covered in complicated skin and skin structure infections drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12940&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of skin disease is expected to propel the growth of the complicated skin and skin structure infections drugs market going forward. Skin diseases are medical conditions that affect the skin’s appearance, structure and function. These conditions can involve the skin, hair, nails and related tissues. Various antibiotic drugs are used to treat resistant bacteria in cSSSI. Thus, the rise in skin disease cases can lead to new cSSSI drug approvals, raise awareness and promote early diagnosis of complicated skin and skin structure infections. For instance, in April 2022, according to the American Academy of Dermatology Association, a US-based non-profit medical specialty association, approximately 9,500 people in the US will be diagnosed with skin cancer daily. Furthermore, in March 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the total number of deaths from fungal infections increased from 5,922 in 2020 to 7,199 in 2021. Therefore, the increasing prevalence of skin disease drives the growth of the complicated skin and skin structure infections drugs market.
Key Industry Players
Major players in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Eli Lilly and Company, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy’s Laboratories Ltd., Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, LEO Pharma, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.
The complicated skin and skin structure infections drugs market report table of contents includes:
- Executive Summary
- Complicated Skin And Skin Structure Infections Drugs Market Characteristics
- Complicated Skin And Skin Structure Infections Drugs Market Trends And Strategies
- Complicated Skin And Skin Structure Infections Drugs Market – Macro Economic Scenario
- Global Complicated Skin And Skin Structure Infections Drugs Market Size and Growth
.
.
.
- Global Complicated Skin And Skin Structure Infections Drugs Market Competitive Benchmarking
- Global Complicated Skin And Skin Structure Infections Drugs Market Competitive Dashboard
- Key Mergers And Acquisitions In Complicated Skin And Skin Structure Infections Drugs Market
- Complicated Skin And Skin Structure Infections Drugs Market Future Outlook and Potential Analysis
- Appendix
Top Major Players :
- Pfizer Inc.
- Johnson & Johnson
- Hoffmann-La Roche Ltd.
- AbbVie Inc
- Bayer AG
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
